Medium materiality6/10
Compass Therapeutics (CMPX) PT Lowered to $4 at Citizens After FDA Dialogue
Why it may matterVerify against the original reporting
bullish
Public signal · 1-minute delayed
Signal brief
Source-backed market context you can read and share without an account.
AI summary
What happened, with direct paths to the underlying reporting
Wedbush target updated to $4 after FDA dialogue; current price $1.24; target remains above the present level indicating upside.
- Wedbush target lowered to $4 after FDA dialogue; price $1.24.
Key facts
- 01
Target: $4
- 02
Posted price: $1.24
- 03
Analyst firm: Wedbush
How to read this signal
Transparent limits for an AI-generated research aid
StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.